Kidney Transplant; ComplicationsNCT06641622
Study of the Correlation Between Donor CIRBP and Transplanted Kidney Function
An observational study of Kidney Transplant; Complications and Delayed Graft Function, run by Third Affiliated Hospital, Sun Yat-Sen University at 1 site in China.
Trial summary
Deceased donors and recipients who successfully completed kidney transplantation between 2016 and 2019 were included in this study. Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence. Read more about this study
- Who is it for?
- Ages 10 to 80 years
- Conditions the study is for
- Kidney Transplant; Complications, Delayed Graft Function
- What is being tested?
- Prediction of delayed graft function
- How many people
- 207 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2023to 10 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Our study was a retrospective open cohort study that included deceased patients from January 2016 to December 2019. It adhered to the guidelines of the National Program for Deceased Organ Donation in China and involved successful kidney donors from the Third Affiliated Hospital of Sun Yat-sen University.
Who may be able to join
- Kidney donors who meet the criteria for donation;
- First-time kidney transplant recipients;
- Transplantation using cadaveric donor kidneys;
- Signing of the Human Organ Donation Relative Acknowledgement Registration Form.
Who cannot join
- those without a blood specimen;
- contamination of the blood specimen affecting the CIRBP level;
- recipients of combined multi-organ transplants;
- those participating in other clinical trials;
- the existence of a previous history of other organ transplants;
- any other condition that, in the opinion of the investigator, makes enrolment unsuitable.
Trial locations and contacts
1 site in 1 country.
China1 site
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510000
About this study
Deceased donors and recipients who successfully completed kidney transplantation between 2016 and 2019 were included in this study. Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence.
Read the detailed description
The study was a retrospective open cohort study that included deceased patients from January 2016 to December 2019. It adhered to the guidelines of the National Program for Deceased Organ Donation in China and involved successful kidney donors from the Third Affiliated Hospital of Sun Yat-sen University. Donors were excluded if they met any of the following conditions: (a) lacked a blood specimen; (b) had contaminated blood specimens affecting CIRBP levels; (c) were recipients who underwent combined multi-organ transplants; (d) were participating in other clinical trials; (e) had a history of organ transplantation; (f) had other conditions deemed unsuitable for enrollment by the investigator. Blood specimens were collected from donors by Organ Procurement Organizations (OPOs) and used for various studies with the donors' consent. All recipients (207 recipients, 207 donors) were followed up in the long term after transplantation.
The investigators followed the principles outlined in the Declaration of Helsinki (20) and the Declaration of Istanbul . Approval for this study was obtained from the Human Organ Transplantation and Ethics Committee of Sun Yat-sen University. The Ethics Committee was formed in compliance with the World Health Organization's Operational Guidelines for Ethics Committee Review of Biomedical Research. Organ allocation was performed in a fair and transparent manner via the Chinese Organ Transplant Response System. The type of donation was voluntarily determined by the donor's family, and the recipient underwent follow-up after transplantation. Both the donor's family and the recipient provided consent for the use of samples and clinical data in research.
Donor data were obtained from the China Organ Transplant Response System, completed by members of organ transplant organizations. Additionally, some donor information was supplemented from clinical electronic medical records. Recipient data were derived from clinical electronic records alone. Investigators categorized donors and recipients into delayed graft function (DGF) and immediate graft function (IGF) groups based on the recipient's early renal function status. DGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery. Recipients who did not develop DGF were categorized as IGF. Primary nonfunction (PNF) was diagnosed in patients requiring continuous dialysis after surgery or retransplantation. Additionally, expended criteria donors were defined as those aged over 60 years, or between 50 and 59 years meeting at least two of the following criteria: final serum creatinine > 133 μmol/L, cerebrovascular accident as the cause of death, and a history of hypertension.
Sample Collection Whole blood specimens were obtained from the donor in the operating theater before organ retrieval and transported on crushed ice to the laboratory, with an average transit duration of 2 hours. For serum preparation, the whole blood specimens were left at room temperature for 2 hours, then centrifuged at 1000 g for 15 minutes at a temperature of 2-8°C. The resulting supernatant was collected and stored at -80°C within the laboratory. Before testing, the serum samples were thawed on crushed ice and centrifuged again at 1000 g for 15 minutes at 2-8°C.
Measurement Of Cold Inducible RNA Binding Protein Level Serum CIRBP was detected using an ELISA kit (CSB-EL005440HU). The protein standard was diluted according to the instructions, and 100 µl of different concentrations of standard and samples (1:10 dilution) were added to a 96-well plate in duplicate. The plate was incubated at 37°C for 2 hours in the dark. Following incubation, the liquid in the wells was discarded, and 100 µl of biotin-labeled antibody working solution was added to each well. After incubating at 37°C for 1 hour, the plate was washed three times with washing solution. Subsequently, 100 µl of horseradish peroxidase-labeled affinity solution was added to each well. After an additional 1-hour incubation at 37°C, the plate was washed five times. Then, 90 µl of substrate solution was added to each well, and after a 15-minute color development at 37°C, 50 µl of termination solution was used to stop the reaction. The absorbance was measured at 450 nm within 5 minutes using a microplate reader, and concentrations were calculated based on the standard curve.
- Being tested
- Prediction of delayed graft function
- Keywords
- kidney transplantation, cold-inducible RNA binding protein, delayed graft function
- Medical subject headings
- Delayed Graft Function
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prediction of delayed graft functionDiagnostic test
Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
| Study group | Role | What they receive |
|---|---|---|
| delayed graft function | DGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery Receives: Diagnostic Test: Prediction of delayed graft function | |
| immediate graft function | Recipients who did not develop DGF were categorized as IGF |
What is being measured
The primary outcome is the main question the study is designed to answer.
recipients developed delayed graft function
DGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery
Measured: within 1 week after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start1 Dec 2023
- Primary completion10 Aug 2024
- Study completion10 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Kidney Transplant; ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 207 participants (actual)
Sponsor and investigators
- Lead sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Qianghua Leng, Third Affiliated Hospital, Sun Yat-Sen University
- Investigators
- Qianghua Leng, Study director, Third Affiliated Hospital, Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06641622
- Sponsor's protocol ID
- II-2024-046-02
- Status last verified
- Oct 2024
- First submitted
- 10 Oct 2024
- Last updated
- 15 Oct 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Share the data on Public management platform for clinical trials ResMan
Publications
Yang R, Zhan M, Nalabothula NR, Yang Q, Indig FE, Carrier F. Functional significance for a heterogenous ribonucleoprotein A18 signature RNA motif in the 3'-untranslated region of ataxia telangiectasia mutated and Rad3-related (ATR) transcript. J Biol Chem. 2010 Mar 19;285(12):8887-93. doi: 10.1074/jbc.M109.013128. Epub 2010 Jan 26.
PubMed 20103595Leng Q, Ma M, Tang Z, Jiang W, Han F, Huang Z. Assessing donor kidney function: the role of CIRBP in predicting delayed graft function post-transplant. Front Immunol. 2025 Jan 17;15:1518279. doi: 10.3389/fimmu.2024.1518279. eCollection 2024.
PubMed 39896811
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Correlation Between Donor CIRBP and Transplanted Kidney Function
- ClinicalTrials.gov ID
- NCT06641622
- Acronym / sponsor ID
- II-2024-046-02
- Keywords
- kidney transplantation, cold-inducible RNA binding protein, delayed graft function
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 207 participants (actual)
- Lead sponsor
- Third Affiliated Hospital, Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 1 Dec 2023 (actual)
- Primary completion
- 10 Aug 2024 (actual)
- Study completion
- 10 Oct 2024 (actual)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Deceased donors and recipients who successfully completed kidney transplantation between 2016 and 2019 were included in this study. Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence.
Detailed description
The study was a retrospective open cohort study that included deceased patients from January 2016 to December 2019. It adhered to the guidelines of the National Program for Deceased Organ Donation in China and involved successful kidney donors from the Third Affiliated Hospital of Sun Yat-sen University. Donors were excluded if they met any of the following conditions: (a) lacked a blood specimen; (b) had contaminated blood specimens affecting CIRBP levels; (c) were recipients who underwent combined multi-organ transplants; (d) were participating in other clinical trials; (e) had a history of organ transplantation; (f) had other conditions deemed unsuitable for enrollment by the investigator. Blood specimens were collected from donors by Organ Procurement Organizations (OPOs) and used for various studies with the donors' consent. All recipients (207 recipients, 207 donors) were followed up in the long term after transplantation.
The investigators followed the principles outlined in the Declaration of Helsinki (20) and the Declaration of Istanbul . Approval for this study was obtained from the Human Organ Transplantation and Ethics Committee of Sun Yat-sen University. The Ethics Committee was formed in compliance with the World Health Organization's Operational Guidelines for Ethics Committee Review of Biomedical Research. Organ allocation was performed in a fair and transparent manner via the Chinese Organ Transplant Response System. The type of donation was voluntarily determined by the donor's family, and the recipient underwent follow-up after transplantation. Both the donor's family and the recipient provided consent for the use of samples and clinical data in research.
Donor data were obtained from the China Organ Transplant Response System, completed by members of organ transplant organizations. Additionally, some donor information was supplemented from clinical electronic medical records. Recipient data were derived from clinical electronic records alone. Investigators categorized donors and recipients into delayed graft function (DGF) and immediate graft function (IGF) groups based on the recipient's early renal function status. DGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery. Recipients who did not develop DGF were categorized as IGF. Primary nonfunction (PNF) was diagnosed in patients requiring continuous dialysis after surgery or retransplantation. Additionally, expended criteria donors were defined as those aged over 60 years, or between 50 and 59 years meeting at least two of the following criteria: final serum creatinine > 133 μmol/L, cerebrovascular accident as the cause of death, and a history of hypertension.
Sample Collection Whole blood specimens were obtained from the donor in the operating theater before organ retrieval and transported on crushed ice to the laboratory, with an average transit duration of 2 hours. For serum preparation, the whole blood specimens were left at room temperature for 2 hours, then centrifuged at 1000 g for 15 minutes at a temperature of 2-8°C. The resulting supernatant was collected and stored at -80°C within the laboratory. Before testing, the serum samples were thawed on crushed ice and centrifuged again at 1000 g for 15 minutes at 2-8°C.
Measurement Of Cold Inducible RNA Binding Protein Level Serum CIRBP was detected using an ELISA kit (CSB-EL005440HU). The protein standard was diluted according to the instructions, and 100 µl of different concentrations of standard and samples (1:10 dilution) were added to a 96-well plate in duplicate. The plate was incubated at 37°C for 2 hours in the dark. Following incubation, the liquid in the wells was discarded, and 100 µl of biotin-labeled antibody working solution was added to each well. After incubating at 37°C for 1 hour, the plate was washed three times with washing solution. Subsequently, 100 µl of horseradish peroxidase-labeled affinity solution was added to each well. After an additional 1-hour incubation at 37°C, the plate was washed five times. Then, 90 µl of substrate solution was added to each well, and after a 15-minute color development at 37°C, 50 µl of termination solution was used to stop the reaction. The absorbance was measured at 450 nm within 5 minutes using a microplate reader, and concentrations were calculated based on the standard curve.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| delayed graft function | – | Diagnostic Test: Prediction of delayed graft functionDGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery |
| immediate graft function | – | –Recipients who did not develop DGF were categorized as IGF |
Who may qualify
- Ages
- 10 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Our study was a retrospective open cohort study that included deceased patients from January 2016 to December 2019. It adhered to the guidelines of the National Program for Deceased Organ Donation in China and involved successful kidney donors from the Third Affiliated Hospital of Sun Yat-sen University.
Key inclusion criteria (4 listed)
- Kidney donors who meet the criteria for donation;
- First-time kidney transplant recipients;
- Transplantation using cadaveric donor kidneys;
- Signing of the Human Organ Donation Relative Acknowledgement Registration Form.
Key exclusion criteria (6 listed)
- those without a blood specimen;
- contamination of the blood specimen affecting the CIRBP level;
- recipients of combined multi-organ transplants;
- those participating in other clinical trials;
- the existence of a previous history of other organ transplants;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prediction of delayed graft functionDonor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence | Diagnostic test | delayed graft function |
Primary outcome
recipients developed delayed graft function
Time frame: within 1 week after surgery
DGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2024.
- Background: PubMed 20103595Yang R, Zhan M, Nalabothula NR, Yang Q, Indig FE, Carrier F. Functional significance for a heterogenous ribonucleoprotein A18 signature RNA motif in the 3'-untranslated region of ataxia telangiectasia mutated and Rad3-related (ATR) transcript. J Biol Chem. 2010 Mar 19;285(12):8887-93. doi: 10.1074/jbc.M109.013128. Epub 2010 Jan 26.
- Derived from this study: PubMed 39896811Leng Q, Ma M, Tang Z, Jiang W, Han F, Huang Z. Assessing donor kidney function: the role of CIRBP in predicting delayed graft function post-transplant. Front Immunol. 2025 Jan 17;15:1518279. doi: 10.3389/fimmu.2024.1518279. eCollection 2024.
- Individual participant dataSharing planned: Yes. Share the data on Public management platform for clinical trials ResMan
Related trials for Kidney Transplant; Complications
RecruitingObservational study
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular Diseases, Kidney Transplant; Complications
Not yet recruitingObservational study
Assessment of Perceived Stress in an Observational Study Evaluating a Biopsy-sparing Surveillance Strategy in Kidney Transplant Recipients With Blood and Urinary Biomarkers Predictive of the Absence of Rejection
Renal Transplantation; Complication, Renal Transplant
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Active, not recruitingPhase 2
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Mucopolysaccharidosis Disorders, Hurler Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Qianghua Leng study director
Third Affiliated Hospital, Sun Yat-Sen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Transplant; Complications and Delayed Graft Function, run by Third Affiliated Hospital, Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
recipients developed delayed graft function (time frame: within 1 week after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06641622, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.